FMS

Business Context and Reporting Period

Company: Fresenius Medical Care AG (FME AG)
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: The world's leading provider of products and services for individuals with renal diseases. Operations are organized into three segments: Care Delivery (dialysis services), Care Enablement (healthcare products and equipment), and Value-Based Care (risk-based kidney care).
Key Structural Change: Pharmaceutical business activities previously reported in Care Enablement were reclassified to Care Delivery for the 2026 periods to reflect organizational management changes. Comparative 2025 data remains unadjusted.

Key Financial Metrics

Note: Free Cash Flow is defined as net cash from operating activities less capital expenditures, before acquisitions and investments.

Material Changes vs. Prior Period

• Revenue: Consolidated revenue decreased 2% (as reported) for the six months ended June 30, 2026, compared to the prior year. This was driven by a negative impact from foreign currency translation (-5%) and the effect of closed or sold operations, partially offset by organic growth of 3%.
• Operating Income: Operating income remained relatively flat (-1% as reported) for the six-month period. Growth was supported by business expansion and net savings from the FME25+ Program, but was offset by inflationary cost increases, the Tavneos Impacts (€71M loss from equity method investees), and higher personnel and IT expenses.
• Net Income: Net income attributable to shareholders decreased 11% to €336M for the six months ended June 30, 2026. The decline was primarily due to the Tavneos Impacts and higher noncontrolling interest allocations.
• Segment Performance:
  • Care Delivery: Revenue decreased 1% (as reported) due to currency and clinic closures, though organic growth was positive. Operating income increased 6%.
  • Care Enablement: Revenue decreased 2% (as reported) due to currency and volume-based procurement pressures in China, offset by strong sales of the 5008X CAREsystem.
  • Value-Based Care: Revenue decreased 1% (as reported) due to currency, but operating income improved from a loss to a profit of €6M.

Guidance, Outlook, and Risks

• Strategic Initiatives: The company is executing the FME25+ Program, targeting cumulative sustainable savings of €1.2 billion by the end of 2027. As of June 30, 2026, €920M in cumulative savings had been achieved.
• Capital Allocation: A new €1 billion share buyback program was launched in May 2026. The company also paid a dividend of €1.49 per share in May 2026.
• Regulatory Risks:
  • U.S. Reimbursement: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes significant Medicaid funding cuts and eligibility restrictions, expected to adversely affect reimbursement levels. The expiration of ACA premium tax credits in late 2025 may shift patients to lower-reimbursement Medicare/Medicaid plans.
  • TDAPA Transition: Favorable impacts from Transitional Drug Add-On Payment Adjustments (TDAPA) supported results in the first half of 2026 but are expected to become a headwind in the second half as drugs transition to the base rate.
• Operational Risks: Inflationary pressures on labor and raw materials, supply chain disruptions due to geopolitical conflicts (Middle East), and the impact of new tariffs on U.S. imports.
• Legal Proceedings: Ongoing investigations include False Claims Act allegations regarding vascular access services, antitrust inquiries by the FTC and state attorneys general, and a German investigation into conduct in West Africa.